Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 74Years
All Genders
NCT05255302

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Led by Intergroupe Francophone de Cancerologie Thoracique · Updated on 2025-04-01

1360

Participants Needed

44

Research Sites

369 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC. As a matter of fact, first registration trials of immune-checkpoints inhibitors (ICI) in second-line settings (pembrolizumab as well as nivolumab or atezolizumab) had stated that ICI could be continued until disease progression or not tolerable toxicity, up to 5 years. This is only for the first-line registration studies that the arbitrary maximal duration of treatment of 2 years was set up by the Companies sponsoring such trials. The aim is to study a de-escalation scheme of treatment from 2 years of immunotherapy to 6 months (27-weeks), in patients with controlled disease.

CONDITIONS

Official Title

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Who Can Participate

Age: 18Years - 74Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent before any study procedures
  • Diagnosed with metastatic NSCLC (stage IV) confirmed by histology or cytology
  • Local assessment of PD-L1 tumor content
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Weight loss less than 10% in the past 3 months
  • No prior systemic anticancer therapy for advanced disease
  • Age 18 to less than 75 years
  • Life expectancy greater than 3 months
  • Measurable tumor by CT or MRI according to RECIST 1.1
  • Adequate tumor tissue available for molecular analysis
  • Adequate biological functions including creatinine clearance ≥ 45 mL/min, neutrophils ≥ 1500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, liver enzymes and bilirubin within specified limits
  • Women of childbearing potential must use effective contraception and have negative pregnancy test
  • Sexually active men must use effective contraception during treatment and 6 months after
  • National health insurance coverage
Not Eligible

You will not qualify if you...

  • Small cell lung cancer or mixed tumors including small cell component
  • Known EGFR activating mutations or HER2 exon 20 insertion
  • Known ALK, ROS1, Ret, NTRK, NRG1 gene rearrangements
  • Previous or active cancer within 3 years except certain treated cancers
  • Persistent superior vena cava syndrome despite stenting
  • Radiotherapy needed at start of treatment except palliative bone radiotherapy
  • Untreated symptomatic brain metastases or recent brain radiotherapy
  • History of primary immunodeficiency or recent immunosuppressive treatment
  • Systemic corticosteroids >10 mg prednisone daily within 14 days before immunotherapy
  • Active autoimmune diseases except certain controlled or benign conditions
  • Active uncontrolled infections including tuberculosis and active hepatitis B or C
  • Known HIV infection
  • Live attenuated vaccine within 30 days prior to study
  • Previous treatment with immune checkpoint inhibitors or chemotherapy for lung cancer
  • Serious uncontrolled cardiac conditions or recent stroke
  • Moderate or severe lung interstitial disease
  • Inability to comply with study or follow-up due to social or psychological reasons
  • Pregnant or breastfeeding women
  • Legal incapacity or inability to consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 44 locations

1

Aix-en-Provence - CH

Aix-en-Provence, France

Not Yet Recruiting

2

Amiens - Clinique de l'Europe

Amiens, France

Not Yet Recruiting

3

Angers - CHU

Angers, France

Not Yet Recruiting

4

Avignon - CH

Avignon, France

Not Yet Recruiting

5

Besançon - CHU

Besançon, France

Not Yet Recruiting

6

Bordeaux - Polyclinique

Bordeaux, France

Not Yet Recruiting

7

CHU de Bordeaux

Bordeaux, France

Not Yet Recruiting

8

Caen - CHU Côte de Nacre

Caen, France, 14000

Actively Recruiting

9

Cannes - CH

Cannes, France

Not Yet Recruiting

10

Chauny - Centre Hospitalier

Chauny, France

Not Yet Recruiting

11

CH

Colmar, France

Not Yet Recruiting

12

Centre Georges François Leclerc

Dijon, France

Not Yet Recruiting

13

CHRU Grenoble

Grenoble, France

Active, Not Recruiting

14

La Roche Sur Yon - CH

La Roche-sur-Yon, France, 85925

Not Yet Recruiting

15

CH de Versailles

Le Chesnay, France

Not Yet Recruiting

16

Centre Hospitalier - Pneumologie

Le Mans, France, 72000

Not Yet Recruiting

17

CHRU de Lille

Lille, France

Not Yet Recruiting

18

CHU de Limoges

Limoges, France

Not Yet Recruiting

19

Lyon - Hôpital Jean Mermoz

Lyon, France

Not Yet Recruiting

20

Marseille - Hôpital Européen

Marseille, France

Not Yet Recruiting

21

Meaux - CH

Meaux, France

Not Yet Recruiting

22

Metz - Hôpital Robert Schuman

Metz, France

Active, Not Recruiting

23

Hôpital Arnaud de Villeneuve

Montpellier, France, 34295

Not Yet Recruiting

24

Centre Hospitalier

Mulhouse, France, 68070

Not Yet Recruiting

25

Nantes - CHU Hôpital Laënnec

Nantes, France

Not Yet Recruiting

26

Nice - CRLCC

Nice, France

Not Yet Recruiting

27

Orléans - CHR

Orléans, France

Not Yet Recruiting

28

Paris - APHP - Hopital Tenon

Paris, France, 75020

Active, Not Recruiting

29

Institut CURIE

Paris, France, 75248

Not Yet Recruiting

30

Hôpital Bichat - Claude - Bernard

Paris, France

Actively Recruiting

31

Reims - CHU

Reims, France

Not Yet Recruiting

32

Rouen - CHU

Rouen, France

Not Yet Recruiting

33

Centre René Huguenin

Saint-Cloud, France, 92210

Not Yet Recruiting

34

CHU Saint-Etienne Pneumologie

Saint-Etienne, France, 42000

Not Yet Recruiting

35

Hôpital privé de la Loire

Saint-Etienne, France

Not Yet Recruiting

36

Institut de Cancérologie de l'Ouest - René Gauducheau

Saint-Herblain, France, 44805

Not Yet Recruiting

37

Saint-Nazaire - Clinique Mutualiste de l'Estuaire

Saint-Nazaire, France

Not Yet Recruiting

38

CHU de La Réunion-Site Sud

Saint-Pierre, France, 97448

Not Yet Recruiting

39

Centre Hospitalier

Saint-Quentin, France, 02100

Not Yet Recruiting

40

Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

Strasbourg, France, 67091

Not Yet Recruiting

41

Centre Hospitalier Intercommunal

Toulon, France

Not Yet Recruiting

42

Hôpital Larrey (CHU)

Toulouse, France, 31059

Not Yet Recruiting

43

CHRU de Tours

Tours, France

Not Yet Recruiting

44

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, France, 54511

Not Yet Recruiting

Loading map...

Research Team

C

Clinical Operations Manager

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction | DecenTrialz